Patient-Reported Quality of Life With ALUNBRIG® (brigatinib)1,2
Methodology: Patient-reported symptoms and QoL were assessed using the validated EORTC QLQ-C30 questionnaire - a tool used worldwide to evaluate quality of life in patients with cancer. It was completed at baseline, day 1 of each 4-week treatment cycle, at end of treatment, and 30 days after the last dose. Time to worsening in GHS/QoL was defined as a ≥10-point decrease from baseline. A total of 262 patients (131 per treatment arm) completed the questionnaire in ALTA-1L.
Limitations:
• Although change from baseline in GHS/QoL was a prespecified secondary endpoint, patient-reported outcomes did not include any formal statistical testing.
• Observed differences in QoL scores and time to worsening may be overestimated due to the open-label study design.
• Fewer patients contributed data at later time points, particularly in the crizotinib arm, primarily due to progression events.
• Results are descriptive and should be interpreted with caution.
Median Time to Worsening in GHS/QoL (≥10-Point Worsening in Score)
Time to worsening was assessed by:
Physical scales
Emotional, cognitive, and social functioning scales
Improvement of disease symptoms
CI, confidence interval; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire–Core 30; GHS, global health status; HR, hazard ratio; NR, not reached.